Research report
Biodistribution of clodronate and liposomes used in the liposome mediated macrophage ‘suicide’ approach

https://doi.org/10.1016/0022-1759(96)00034-8Get rights and content

Abstract

Clodronate (Cl2MBP; dichloromethylene-bisphosphonate)-containing liposomes are used to investigate the role of macrophages in immune and non-immune defense mechanisms by elimination of these macrophages followed by functional studies. The present studies characterize such liposomes in terms of the leakage of clodronate and the biodistribution of both the encapsulated drug and the liposomal carrier. The distribution of liposomes was studied using a radioactively labelled lipid phase marker (111In-DTPA-SA) and the distribution of the encapsulated drug was examined following injection of radioactively labelled clodronate (99mTc-Cl2MBP). Furthermore, the biodistribution of variously composed multilamellar liposomes (EPC/Chol molar ratio 7:1.3 or 7:7; EPC/Chol/PS 7:1.3:1 or 7:7:1; EPC/Chol/M 7:2:1; EPC/Chol/MPE 7:2:1) after intravenous injection was investigated. The findings suggest that only one third of the originally entrapped clodronate was still encapsulated in the liposomes at the time of ingestion by the macrophages in the liver and spleen after intravenous injection of the clodronate containing liposomes. 3 h after injection no clodronate could be detected in the circulation.

References (21)

There are more references available in the full text version of this article.

Cited by (35)

  • Liposome encapsulated clodronate mediated elimination of pathogenic macrophages and microglia: A promising pharmacological regime to defuse cytokine storm in COVID-19

    2022, Medicine in Drug Discovery
    Citation Excerpt :

    It has been reported that intravenous administration of 20 mg of clodronate encapsulated with unilamellar liposomes significantly reduced macrophages and diminished inflammation in an experimental rat model of arthritis, while treatment of free clodronate had no effect in targeting macrophages [93,94]. The radioactive labelling-based animal experiments by Buiting have already demonstrated the in vivo distribution of clodronate in various organs including the liver and spleen [95]. Besides, the whole animal in vivo experiments described that the use of clodronate-liposome solution leads to efficient depletion of macrophages in the bone marrow, spleen, liver, lungs, brain, gut, peritoneal cavity, lymph nodes and in circulation thereby, suggesting liposome-encapsulated clodronate can spread to various organs in the body [96] (Figs. 2, 3, 4).

  • Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice

    2017, Molecular Therapy Methods and Clinical Development
    Citation Excerpt :

    Liposomal clodronate pretreatment did not improve MΦ survival, though this may be due to residual liposomal clodronate killing transplanted MΦs. Liposomal clodronate injected intravenously (i.v.) is not detectable in the blood 3 hr post-injection,46 but administration i.p. may extend the overall clearance time. This may be addressed by a different injection schedule to allow for the clearance of liposomal clodronate before transplantation of MΦs.

  • Liposomal alendronate for the treatment of restenosis

    2012, Journal of Controlled Release
    Citation Excerpt :

    The mechanisms of cell death could play a role in tissues in which liposomes accumulate. In the vascular injury model (restenosis), since liposomal BPs deplete circulating monocytes which act as the transporters, they do not accumulate in the arterial wall [50, 58, 59, 92], but are disposed to some extent in other tissues (mainly the liver and spleen [50, 84, 87, 93]). Our results indicate that accumulation of LA in tissues does not induce side effects subsequent to cell necrosis.

View all citing articles on Scopus

Correspondence to: T. Sminia, Department of Cell Biology and Immunology, Faculty of Medicine, Vrije Universiteit, Van der Boechorststraat 7, 1081 BT Amsterdam, Netherlands. Fax: (31)204448081.

2

Present address: GI Cell Biology Laboratory, Children's Hospital, Harvard Medical School, Boston, MA, USA.

View full text